

BRIEF COMMUNICATION

Reassessing the association: Evaluation of a polyalanine deletion variant of *RUNX2* in non-syndromic sagittal and metopic craniosynostosis

Isaac S. Walton¹  | Emma McCann² | Astrid Weber² | Jenny E. V. Morton^{3,4} | Peter Noons⁴ | Louise C. Wilson⁵ | Rosanna C. Ching⁶ | Deirdre Cilliers⁷ | David Johnson⁶ | Julie M. Phipps⁷ | Deborah J. Shears^{6,7} | Gregory P. L. Thomas⁶  | Steven A. Wall⁶ | Stephen R. F. Twigg¹  | Andrew O. M. Wilkie^{1,6,7} 

¹MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK

²Department of Clinical Genetics, Liverpool Women's NHS Foundation Trust, Liverpool, England, UK

³West Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's Hospitals NHS Foundation Trust, Birmingham, UK

⁴Birmingham Craniofacial Unit, Birmingham Women's and Children's Hospitals NHS Foundation Trust, Birmingham, UK

⁵Clinical Genetics Service, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

⁶Oxford Craniofacial Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

⁷Oxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Correspondence

Andrew O. M. Wilkie, MRC Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK.

Email: andrew.wilkie@imm.ox.ac.uk

Present address

Emma McCann, Department of Clinical Genetics, CHI at Crumlin, Dublin, Ireland

Funding information

Clarendon Fund; VTCT Foundation; Somerville College, University of Oxford; NIHR Oxford Biomedical Research Centre; Radcliffe Department of Medicine, University of Oxford; Medical Research Council, Grant/Award Number: MR/N013468/1; Wellcome Trust, Grant/Award Number: 102731

Abstract

The RUNT-related transcription factor *RUNX2* plays a critical role in osteoblast differentiation, and alterations to gene dosage cause distinct craniofacial anomalies. Uniquely amongst the RUNT-related family, vertebrate *RUNX2* encodes a polyglutamine/polyalanine repeat (Gln₂₃-Glu-Ala₁₇ in humans), with the length of the polyalanine component completely conserved in great apes. Surprisingly, a frequent 6-amino acid deletion polymorphism, p.(Ala84_Ala89)del, occurs in humans (termed 11A allele), and a previous association study (Cuellar et al. *Bone* **137**:115395;2020) reported that the 11A variant was significantly more frequent in non-syndromic sagittal craniosynostosis (nsSag; allele frequency [AF]=0.156; 95% confidence interval [CI] 0.126–0.189) compared to non-syndromic metopic craniosynostosis (nsMet; AF=0.068; 95% CI 0.045–0.098). However, the gnomAD v.2.1.1 control population used by Cuellar et al. did not display Hardy–Weinberg equilibrium, hampering interpretation. To re-examine this association, we genotyped the *RUNX2* 11A polymorphism in 225 individuals with sporadic nsSag as parent–child trios and 164 singletons with sporadic nsMet, restricting our analysis to individuals of European ancestry. We compared observed allele frequencies to the non-transmitted alleles in the parent–child trios, and

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Authors. *Journal of Anatomy* published by John Wiley & Sons Ltd on behalf of Anatomical Society.

to the genome sequencing data from gnomAD v.4, which display Hardy–Weinberg equilibrium. Observed AFs (and 95% CI) were 0.076 (0.053–0.104) in nsSag and 0.082 (0.055–0.118) in nsMet, compared with 0.062 (0.042–0.089) in non-transmitted parental alleles and 0.065 (0.063–0.067) in gnomAD v.4.0.0 non-Finnish European control genomes. In summary, we observed a non-significant excess, compared to gnomAD data, of 11A alleles in both nsSag (relative risk 1.18, 95% CI 0.83–1.67) and nsMet (relative risk 1.29, 95% CI 0.87–1.92), but we did not replicate the much higher excess of *RUNX2* 11A alleles in nsSag previously reported ($p=0.0001$).

KEYWORDS

craniosynostosis, genetic association, metopic synostosis, polyalanine, *RUNX2*, sagittal synostosis

1 | INTRODUCTION

Although great progress has been made in determining the genetic causes of syndromic craniosynostosis over the past 30 years, understanding the origins of non-syndromic single suture craniosynostosis has lagged behind. The virtual absence of extensive pedigrees segregating these phenotypes demonstrates that these are rarely simple Mendelian conditions; instead, a complex mixture of environmental factors, polygenes, and monogenic alleles with reduced penetrance and variable expressivity are likely responsible, with different (but currently unmeasurable) relative contributions of these factors in different individuals who appear to be affected with similar phenotypes (Twigg & Wilkie, 2015).

Non-syndromic craniosynostosis most commonly involves the midline sutures, with non-syndromic metopic (nsMet) and sagittal (nsSag) synostosis accounting for 15%–20% and 35%–40% of all cases of craniosynostosis, respectively (Gaillard et al., 2023; Wilkie et al., 2017). Although the metopic and sagittal sutures themselves are both of neural crest origin, their bony margins have different origins; the frontal bones bordering the metopic suture are neural crest-derived, whereas the parietal bones bordering the sagittal suture originate from cephalic mesoderm (Jiang et al., 2002). These differences in developmental embryology of the sutures could underlie differences in developmental pathology between nsMet and nsSag.

Although the genetic factors contributing to non-syndromic midline craniosynostosis remain poorly characterised, a few robust observations have been made. In both nsMet and nsSag, heterozygous pathogenic variants in *SMAD6* are the most important monogenic (Mendelian) contributor, being observed in ~5% nsMet and ~1% nsSag (Calpena et al., 2020; Di Rocco et al., 2023; Timberlake et al., 2016, 2017). The role played by de novo mutations in other genes remains controversial (Kiziltug et al., 2023; Timberlake et al., 2017). Only two genome-wide association studies (GWAS) of craniosynostosis have been published. In 2012, a GWAS of nsSag identified two significant loci, on chromosome 20 near *BMP2* and on chromosome 7 within *BBS9*, with the lead single-nucleotide polymorphisms (SNPs) exhibiting highly significant odds ratios (4.38 and 4.17 in the meta-analyses, respectively), compared to controls (Justice et al., 2012). A more

recent similar study of nsMet identified one replicated genome-wide significant SNP, located within *BMP7* (meta-analysis odds ratio 1.74 compared to controls) (Justice et al., 2020).

The starting point for this work was a previous investigation of the *RUNX2* gene in nsSag and nsMet (Cuellar et al., 2020). *RUNX2*, one of three vertebrate family members related to the *Drosophila* gene *runt*, encodes a transcription factor that acts as a master regulator of osteoblast differentiation (Ducy et al., 1997; Otto et al., 1997). Haploinsufficiency of *RUNX2* causes cleidocranial dysplasia type 1 (CLCD1; OMIM 119600), a condition characterised by the reduced ossification of the skull and additional skeletal abnormalities including absent lateral portions of the clavicle, short stature, and severe dental anomalies (Lee et al., 1997; Mundlos et al., 1997). Contrastingly, increased *RUNX2* dosage is a known (but rare) cause of craniosynostosis (Greives et al., 2013; Mefford et al., 2010; Varvagiannis et al., 2013). Following exploratory sequencing of *RUNX2* in a small cohort of individuals with nsSag, Cuellar et al. (2020) undertook further targeted investigations of an 18-nucleotide *RUNX2* deletion variant, NM_001024630.4:c.243_260del (rs11498192), encoding p.(Ala84_Ala89)del; this variant, subsequently referred to as 11A, lies within a long tract of imperfect triplet repeats that normally encode the sequence (Gln)₂₃Glu(Ala)₁₇, thus reducing the length of the polyalanine section from 17 (wild-type [WT] allele), to 11 residues.

The results of the work by Cuellar et al. (2020), and their interpretation, are summarised in Table 1 (topmost three lines). A highly significant 2.3-fold higher prevalence of 11A alleles was observed in nsSag (AF=0.156) compared with nsMet (AF=0.068) ($p=3.1 \times 10^{-4}$). However, interpretation of this finding was impeded because the control population used as a comparator, from gnomAD v2.1.1 non-Finnish European (NFE) individuals mostly analysed by exome sequencing (Table 1, third line), deviated grossly from Hardy–Weinberg equilibrium (HWE) and the gnomAD data were flagged as being suspect (Karczewski et al., 2020). The existence of a robust association between *RUNX2* 11A and the prevalence of nsSag would have major significance for understanding the pathogenesis of non-syndromic craniosynostosis, so we decided to reinvestigate these observations, with the aim of first, establishing a reliable background allele frequency (AF) of 11A in the NFE population, and second, genotyping

TABLE 1 Genotyping summary of *RUNX2* 11A deletion allele in Cuellar et al. (2020), gnomAD, and this work.

	Number of individuals	Number of alleles	Number of heterozygotes	Number of homozygotes	Hardy-Weinberg equilibrium test	Allele frequency	95% CI for allele frequency	Odds ratio (95% CI) ^a
nsSag (Cuellar et al., 2020)	270	540		84 ^b	N/A	0.156	0.126-0.189	2.65 (2.1-3.36)
nsMet (Cuellar et al., 2020)	191	382		26 ^b	N/A	0.068	0.045-0.098	1.05 (0.71-1.57)
gnomAD v2.1.1 (NFE) ^c	44,956	88,912	4973	1170	<1 e-10	0.081	na	na
nsSag (this work)	225	450	32	1	0.79	0.076	0.053-0.104	1.18 (0.83-1.67)
nsSag - non-transmitted allele from parent (this work)	450	450		28 ^b	na	0.062	0.042-0.089	0.96 (0.65-1.4)
nsMet (this work)	164	328	25	1	0.91	0.082	0.055-0.118	1.29 (0.87-1.92)
gnomAD v4.0.0 genomes (NFE)	33,852	67,704	4115	139	0.75	0.0649	0.063-0.067	na

Abbreviations: NFE, non-Finnish European; N/A, not available; na, not applicable.

^aOdds ratios compared to gnomAD v4.0.0 genomes.

^bTotal number of mutant alleles.

^cData flagged in gnomAD v2.1.1 as likely inaccurate.

an independent cohort of nsSag and nsMet subjects, to see if we could replicate the original findings.

2 | METHODS

2.1 | Patients

Ethical approval was obtained from London-Riverside Research Ethics Committee to collect peripheral blood samples for this work (reference 09/H0706/20). Written informed consent was provided to obtain all samples. DNA samples were either blood-derived or extracted from Epstein-Barr transformed lymphocyte cultures. To match the cohorts used in Cuellar et al. (2020), 225 nsSag proband and parent trios were selected for the transmission disequilibrium test based on white ethnicity, unaffected parents, and no known genetic cause. The 164 nsMet singleton samples were selected solely on white ethnicity, and no known genetic cause.

2.2 | Polymerase chain reaction (PCR)

Primers [forward (5'-CCCTCCAGCAGCCTGCAGCCC-3') and reverse (5'-GGTCGGCGATGATCTCCACCATGG-3')] were designed to GRCh38 chr6:45422622-45,422,859, yielding a 238bp amplicon covering *RUNX2* exon 2, including the entire Gln₂₃GluAla₁₇ region. Roche FastStart™ Taq Polymerase was used with a modified master mix incorporating 20% dimethylsulphoxide, 1x FastStart™ Taq Reaction Buffer, 0.05 μM forward primer, 0.05 μM reverse primer, 0.5 mM dNTPs, 0.16 μL FastStart™ Taq DNA Polymerase, 20ng DNA, and nuclease-free water for a final reaction volume of 20 μL, amplified with optimised thermocycling (Supplementary Table S1).

PCR products were separated by electrophoresis on a 4% agarose gel and scored for the deletion allele (Supplementary Figure S1A).

Samples with atypical results were re-run and, if necessary, dideoxy-sequenced following gel extraction (Monarch DNA Gel extraction kit). One nsMet proband screened was heterozygous for a 12bp tandem duplication (c.174_185dup) in the polyglutamine-encoding region upstream of 11A (Supplementary Figure S1B); sequencing of the polyalanine repeat confirmed a normal (WT/WT) genotype.

2.3 | Statistical tests

A transmission disequilibrium test was applied to the nsSag trios (Spielman et al., 1993). Fisher's exact test was used when comparing allele frequencies. Confidence limits for allele frequencies were calculated following the binomial distribution. Confidence limits for odds ratios (Morris & Gardner, 1988) were calculated from the Select Statistical Services website (<https://select-statistics.co.uk/calculators/confidence-interval-calculator-odds-ratio/>).

3 | RESULTS

Initially, we genotyped the 11A deletion allele in 225 nsSag trios, each comprising a sporadically affected child and both their unaffected parents. Complete results are shown in Table 1 and Supplementary Figure S2. The observed AF in nsSag probands was 0.076, less than half the value obtained by Cuellar et al. (2020), a highly significant difference ($p=0.0001$, Fisher's exact test). Fifty-five parents were heterozygous for 11A and hence informative for transmission: 11A was transmitted in 31 instances and not transmitted in 24, yielding a

transmission proportion of 0.56 (95% CI 0.42–0.7). The background 11A AF in the sampled population, estimated by counting the non-transmitted alleles in these trios, was 0.062 (95% CI 0.042–0.089) (Table 1). This figure is very similar to the 11A AF in NFE gnomAD v.4.0.0 genomes (0.065; 95% CI 0.063–0.067); importantly unlike the equivalent exome data, the three WT/11A genotypes are present in HWE (Table 1). Using the gnomAD v.4.0.0 genome data as the control population, the prevalence of 11A alleles in nsSag was mildly but not significantly elevated (odds ratio 1.18, 95% CI 0.83–1.67).

Finally, we also examined the prevalence of 11A alleles in 164 subjects sporadically affected with nsMet (we did not genotype their parents). Similar to nsSag, we found a mildly but not significantly elevated odds ratio (1.29; 95% CI 0.87–1.92), compared to gnomAD v.4.0.0 genome controls (Table 1).

4 | DISCUSSION

Given the role of *RUNX2* as a master regulator of osteogenesis and the usually high mutability of triplet repeats, the persistence of the poly(Gln_xAla_y) motif in a wide range of vertebrate species is intriguing (Newton & Pask, 2020). Functional significance is also implied by the conservation of (Ala)₁₇ copy number in all great apes, and the fact that a variety of different codons encode the Gln and Ala amino acids (thus helping to reduce, but not eliminate, the occurrence of replication slippage). Although transactivation studies have produced conflicting data, with inhibitory, neutral, or activating effects all reported with the 11A variant (Cuellar et al., 2020; Morrison et al., 2013; Thirunavukkarasu et al., 1998), overall these studies suggest a functional consequence of altering the length of the normal poly(Ala)₁₇ motif, in part through altering binding to the partner protein Core binding factor beta (CBFB) (Morrison et al., 2013; Thirunavukkarasu et al., 1998). This naturally raises the question of whether the 11A variant might be associated with variation either in continuous phenotypic traits, or in disease states.

When considering this question, it is important to note that the 11A variant arises from deletion of one of a tandemly repeated pair of the 18-nucleotide sequence G(GCG)(GCT)(GCG)₃GC (where brackets enclose sequential alanine codons). Hence, it is likely that the 11A deletion has arisen independently multiple times during human evolution through replication slippage and therefore will not be tagged by linkage disequilibrium with a neighbouring SNP. The consequence is that any phenotypic effects of the 11A are unlikely to be detectable using conventional GWAS; rather, directed genotyping of the variant must be undertaken, either using a targeted assay (as presented here, see Supplementary Figure S1A) or by dideoxy- or next-generation sequencing (NGS). Importantly, all three approaches may be associated with technical problems leading to inaccurate genotyping. Our PCR-based gel electrophoresis method will also detect other rearrangements of the amplicon, which are predicted from gnomAD v.4.0.0 data collectively to occur at 7.4% of the frequency of 11A alone in the NFE population (Supplementary Table S2); indeed, we identified one atypical sequence based

on aberrant migration of fragments on the gel (Supplementary Figure S1B). However, sequencing approaches (whether dideoxy- or NGS-based) may be associated with systematic alignment and genotyping errors; undercalling of heterozygotes in low-complexity regions is a known problem with NGS technology (Fuentes Fajardo et al., 2012). This is clearly illustrated by the gross deviation from HWE of the gnomAD v2.1.1 exome sequencing data used as a control by Cuellar et al. (2020). Interestingly, in the current version (v.4.1.0) of gnomAD, the 11A genotypes based on exome (but not genome) sequence continue to deviate grossly from HWE; this is accompanied by a “Discrepant frequencies” warning flag.

Notwithstanding these caveats, previous lines of evidence support that the 11A allele is associated with variation in several phenotypic traits. Morrison et al. (2013) reported that the 11A allele is associated with reduced serum collagen crosslinks, consistent with decreased bone turnover, and that 11A carriers were nearly twice as likely to have sustained fracture, with fractures biased towards bones of intramembranous rather than endochondral origin. Consistent with this, phenotype-wide association studies (PheWAS) from UK Biobank data (Karczewski et al., 2022) identified significant associations of 11A with several bone-related traits including heel bone mineral density, phosphate, standing and sitting height, and forced vital capacity (Supplementary Figure S3).

In the context of these observations, the proposed strong association of 11A with nsSag identified by Cuellar et al. (2020) is intriguing. However, we have not been able to replicate their observations in our own cohort, and we note several issues with the data reported by Cuellar et al. (2020), including inconsistencies in presentation of the numbers of genotypes obtained, variation in the genotyping method used for different cohorts, and failure to confirm HWE in either case or control data. Thus, we conclude that much larger studies will be required to confirm whether the *RUNX2* 11A variant is indeed associated with susceptibility to non-syndromic craniosynostosis, and if so to confirm the effect size.

AUTHOR CONTRIBUTIONS

Study conception and design: AOMW. Providing patient samples: EM, AW, JEV, PN, LCW, RCC, DC, DJ, JMP, DJS, GPLT, SAW, AOMW. Experimental data collection: ISW. Analysis and interpretation: ISW, SRFT, AOMW. Draft manuscript preparation: ISW, AOMW. Critical review of manuscript: ISW, SRFT, AOMW.

ACKNOWLEDGEMENTS

The authors thank all families who contributed to this study. The graphical abstract incorporates artwork created by Servier Medical Art, which has been modified for use under a CC BY 4.0 license. I.S.W. was supported by the Medical Research Council (MR/N013468/1), a Clarendon Fund and Mary Somerville Graduate Scholarship, and a Radcliffe Department of Medicine Scholarship. This work was supported by a Wellcome Investigator Award (102731 to A.O.M.W.), the VTCT Foundation (S.R.F.T., A.O.M.W.), and the NIHR Oxford Biomedical Research Centre (S.R.F.T., A.O.M.W.). The authors declare that they have no conflicts of interest.

DATA AVAILABILITY STATEMENT

The nsSag trio genotyping results that support the findings of this study are available in the supplementary material of this article. The raw data (4% agarose gel images and 11A allele scoring) for genotyping nsSag trios and nsMet samples that support the findings of this study are available from the corresponding author upon request.

ORCID

Isaac S. Walton  <https://orcid.org/0000-0001-9711-7595>

Gregory P. L. Thomas  <https://orcid.org/0000-0003-3122-3939>

Stephen R. F. Twigg  <https://orcid.org/0000-0001-5024-049X>

Andrew O. M. Wilkie  <https://orcid.org/0000-0002-2972-5481>

REFERENCES

- Calpena, E., Cuellar, A., Bala, K., Swagemakers, S.M.A., Koelling, N., MCGowan, S.J. et al. (2020) SMAD6 variants in craniosynostosis: genotype and phenotype evaluation. *Genetics in Medicine*, 22, 1498–1506.
- Cuellar, A., Bala, K., DI Pietro, L., Barba, M., Yagnik, G., Liu, J.L. et al. (2020) Gain-of-function variants and overexpression of RUNX2 in patients with nonsyndromic midline craniosynostosis. *Bone*, 137, 115395.
- DI Rocco, F., Rossi, M., Verlut, I., Szathmari, A., Beuriat, P.A., Chatron, N. et al. (2023) Clinical interest of molecular study in cases of isolated midline craniosynostosis. *European Journal of Human Genetics*, 31, 621–628.
- Ducy, P., Zhang, R., Geoffroy, V., Ridall, A.L. & Karsenty, G. (1997) *Osf2/Cbfa1*: a transcriptional activator of osteoblast differentiation. *Cell*, 89, 747–754.
- Fuentes Fajardo, K.V., Adams, D., Mason, C.E., Sincan, M., Tiffit, C., Toro, C. et al. (2012) Detecting false-positive signals in exome sequencing. *Human Mutation*, 33, 609–613.
- Gaillard, L., Goverde, A., Weerts, M.J.A., DE Klein, A., Mathijssen, I.M.J. & Van Dooren, M.F. (2023) Genetic diagnostic yield in an 11-year cohort of craniosynostosis patients. *European Journal of Medical Genetics*, 66, 104843.
- Greives, M.R., Odessey, E.A., Waggoner, D.J., Shenaq, D.S., Aradhya, S., Mitchell, A. et al. (2013) RUNX2 quadruplication: additional evidence toward a new form of syndromic craniosynostosis. *The Journal of Craniofacial Surgery*, 24, 126–129.
- Jiang, X., Iseki, S., Maxson, R.E., Sucov, H.M. & Morriss-Kay, G.M. (2002) Tissue origins and interactions in the mammalian skull vault. *Developmental Biology*, 241, 106–116.
- Justice, C.M., Cuellar, A., Bala, K., Sabourin, J.A., Cunningham, M.L., Crawford, K. et al. (2020) A genome-wide association study implicates the BMP7 locus as a risk factor for nonsyndromic metopic craniosynostosis. *Human Genetics*, 139, 1077–1090.
- Justice, C.M., Yagnik, G., Kim, Y., Peter, I., Jabs, E.W., Erazo, M. et al. (2012) A genome-wide association study identifies susceptibility loci for nonsyndromic sagittal craniosynostosis near BMP2 and within BBS9. *Nature Genetics*, 44, 1360–1364.
- Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q. et al. (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*, 581, 434–443.
- Karczewski, K.J., Solomonson, M., Chao, K.R., Goodrich, J.K., Tiao, G., Lu, W. et al. (2022) Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK biobank exomes. *Cell Genomics*, 2, 100168.
- Kiziltug, E., Duy, P.Q., Allington, G., Timberlake, A.T., Kawaguchi, R., Long, A.S. et al. (2023) Concurrent impact of de novo mutations on cranial and cortical development in nonsyndromic craniosynostosis. *Journal of Neurosurgery: Pediatrics*, 1, 1–14.
- Lee, B., Thirunavukkarasu, K., Zhou, L., Pastore, L., Baldini, A., Hecht, J. et al. (1997) Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/CBFA1 in cleidocranial dysplasia. *Nature Genetics*, 16, 307–310.

Mefford, H.C., Shafer, N., Antonacci, F., Tsai, J.M., Park, S.S., Hing, A.V. et al. (2010) Copy number variation analysis in single-suture craniosynostosis: multiple rare variants including RUNX2 duplication in two cousins with metopic craniosynostosis. *American Journal of Medical Genetics Part A*, 152A, 2203–2210.

Morris, J.A. & Gardner, M.J. (1988) Statistics in medicine: calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. *BMJ*, 296, 1313–1316.

Morrison, N.A., Stephens, A.S., Osato, M., Pasco, J.A., Fozzard, N., Stein, G.S. et al. (2013) Polyalanine repeat polymorphism in RUNX2 is associated with site-specific fracture in post-menopausal females. *PLoS One*, 8, e72740.

Mundlos, S., Otto, F., Mundlos, C., Mulliken, J.B., Aylsworth, A.S., Albright, S. et al. (1997) Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. *Cell*, 89, 773–779.

Newton, A.H. & Pask, A.J. (2020) Evolution and expansion of the RUNX2 QA repeat corresponds with the emergence of vertebrate complexity. *Communications Biology*, 3, 771.

Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C., Rosewell, I.R. et al. (1997) *Cbfa1*, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell*, 89, 765–771.

Spielman, R.S., McGinnis, R.E. & Ewens, W.J. (1993) Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). *American Journal of Human Genetics*, 52, 506–516.

Thirunavukkarasu, K., Mahajan, M., McLaren, K.W., Stifani, S. & Karsenty, G. (1998) Two domains unique to osteoblast-specific transcription factor *Osf2/Cbfa1* contribute to its transactivation function and its inability to heterodimerize with *Cbfb*. *Molecular and Cellular Biology*, 18, 4197–4208.

Timberlake, A.T., Choi, J., Zaidi, S., Lu, Q., NELSON-Williams, C., Brooks, E.D. et al. (2016) Two locus inheritance of non-syndromic midline craniosynostosis via rare SMAD6 and common BMP2 alleles. *eLife*, 5, e20125.

Timberlake, A.T., Furey, C.G., Choi, J., NELSON-Williams, C., Loring, E., Galm, A. et al. (2017) De novo mutations in inhibitors of Wnt, bmp, and Ras/ERK signaling pathways in non-syndromic midline craniosynostosis. *Proceedings of the National Academy of Sciences*, 114, E7341–E7347.

Twigg, S.R.F. & Wilkie, A.O.M. (2015) A genetic-pathophysiological framework for craniosynostosis. *The American Journal of Human Genetics*, 97, 359–377.

Varvagiannis, K., Stefanidou, A., Gyftodimou, Y., Lord, H., Williams, L., Sarri, C. et al. (2013) Pure de novo partial trisomy 6p in a girl with craniosynostosis. *American Journal of Medical Genetics Part A*, 161, 343–351.

Wilkie, A.O.M., Johnson, D. & Wall, S.A. (2017) Clinical genetics of craniosynostosis. *Current Opinion in Pediatrics*, 29, 622–628.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Walton, I.S., McCann, E., Weber, A., Morton, J.E.V., Noons, P., Wilson, L.C. et al. (2024) Reassessing the association: Evaluation of a polyalanine deletion variant of RUNX2 in non-syndromic sagittal and metopic craniosynostosis. *Journal of Anatomy*, 00, 1–5.
Available from: <https://doi.org/10.1111/joa.14052>